The Bio-Plex Pro SARS-CoV-2 Serology Assays* provide COVID-19 researchers with sensitive and specific assays to monitor the antibody immune response profile against four viral antigens. There are three isotype-specific 4-plex panels that measure antibodies against SARS-CoV-2 Nucleocapsid, Receptor Binding Domain, Spike 1, and Spike 2 viral proteins. The isotype-specific antibodies detected are IgA, IgG, and IgM, providing the spectrum of humoral response over time after COVID-19 vaccine administration or natural exposure to SARS-CoV-2.
Serology Assays Ordering Information »
Bio-Plex Pro SARS-CoV-2 neutralization assays allow researchers to assess the efficacy of COVID-19 vaccines and compare effectiveness of naturally acquired or vaccine-induced antibody response to arising variants of concern. These highly precise and sensitive assays quantitatively measure SARS-CoV-2 neutralizing antibodies against two wild type and 11 variants of receptor binding domain and spike 1 protein subunits. Antigens are coated on magnetic beads that bind neutralizing antibodies in competition with a biotinylated detection ACE-2 receptor.
SARS-CoV-2 Wild Type and Variant S1 and RBD Antigens
Wild type RBD
Wild type S1
Alpha S1
Beta S1Equitable access to safe and effective vaccines is critical to ending the COVID-19 pandemic, so it is hugely encouraging to see so many vaccines proving and going into development. WHO is working tirelessly with partners to develop, manufacture and deploy safe and effective vaccines.
Safe and effective vaccines are a game-changing tool: but for the foreseeable future we must continue wearing masks, cleaning our hands, ensuring good ventilation indoors, physically distancing and avoiding crowds
Being vaccinated does not mean that we can throw caution to the wind and put ourselves and others at risk, particularly because research is still ongoing into how much vaccines protect not only against disease but also against infection and transmissio
See WHO’s landscape of COVID-19 vaccine candidates for the latest information on vaccines in clinical and pre-clinical development, generally updated twice a week. WHO’s COVID-19 dashboard, updated daily, also features the number of vaccine doses administered globally, with more detail provided on the dedicated COVID-19 vaccination dashboard. At a regional level, there is an AFRO COVID-19 vaccines dashboard and a PAHO COVID-19 vaccines deliveries dashboard
But it’s not vaccines that will stop the pandemic, it’s vaccination. We must ensure fair and equitable access to vaccines, and ensure every country receives them and can roll them out to protect their people, starting with the most vulnerabl
You can follow the status of COVID-19 Vaccines within WHO EUL/PQ evaluation process here.Bringing a new vaccine to the public involves many steps including vaccine development, clinical trials, U.S. Food and Drug Administration (FDA) authorization or approval, manufacturing, and distribution. Many different public organizations and private companies have worked together to make COVID-19 vaccines available to the public. While COVID-19 vaccines were developed rapidly, all steps have been taken to ensure their safety and effectiveness.
The Vaccine Process: From the Lab to You
Initial Development
illustration of microscope
New vaccines are first developed in laboratories. Scientists have been working for many years to develop vaccines against coronaviruses, such as those that cause severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS). SARS-CoV-2, the virus that causes COVID-19, is related to these other coronaviruses. The knowledge that was gained through past research on coronavirus vaccines helped speed up the initial development of the current COVID-19 vaccines.
e.. n..
You must be logged in to post a comment.